modelPeginterferonAlfa2aCombi
Extends from Pharmacolibrary.Drugs.ATC.L.L03AB61.
Information
| name: | PeginterferonAlfa2aCombinations | |
| ATC code: | L03AB61 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 180 | mg |
| volume of distribution: | 8 | L |
| clearance: | 100 | mL/h |
| other parameters in model implementation | ||
Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an immunomodulatory agent used primarily in the treatment of chronic hepatitis B and C infections, often in combination with antiviral medications such as ribavirin. Peginterferon alfa-2a is still used, but its clinical use has declined with the advent of direct-acting antivirals.
Pharmacokinetics
Pharmacokinetic parameters have been evaluated mainly in adult patients with chronic hepatitis C, both male and female, generally aged 18–65 years, with or without cirrhosis, receiving subcutaneous weekly administration.
References
Keating, GM, & Curran, MP (2003). Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 63(7) 701–730. DOI:10.2165/00003495-200363070-00008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12656650
Howell, CD, et al., & Hoofnagle, JH (2008). Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 6(5) 575–583. DOI:10.1016/j.cgh.2008.02.035 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18407798
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)